NGNENasdaqPharmaceutical PreparationsUS GAAP · USD

Neurogene Inc.

Neurogene Inc. is a U.S.-based biotechnology company focused on developing gene therapy product candidates for severe neurological diseases. Its pipeline includes programs such as NGN-401 for Rett syndrome and NGN-101 for Batten disease, with research, manufacturing, and clinical development activities centered in the United States.

Ask about the company
Revenue0.0m USD
−100.0 %y/y
Operating profit (EBIT)-103m USD
−25.1 %y/y
Net income-90.4m USD
−20.2 %y/y
Free cash flow-78.4m USD
−9.7 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-125-100-75-50-25025m USD2020: EBIT -34 m USD20202021: EBIT -61 m USD20212022: EBIT -57 m USD20222023: 0.00 m USD2023: EBIT -56 m USD20232024: 0.93 m USD2024: EBIT -83 m USD20242025: 0.00 m USD2025: EBIT -103 m USD20250.00-103
RevenueOperating profit (EBIT)

Business

Share of revenue
Clinical-stage gene therapy programs70 %

Includes lead and pipeline gene therapy candidates advancing through preclinical and clinical development.

Early discovery programs20 %

Includes internal discovery work and earlier-stage neurological disease programs not yet in clinical testing.

Licensing and legacy asset monetization10 %

Includes licensing revenue tied to legacy Neoleukin assets and related agreements.

Customers

Neurogene does not currently sell approved products, so its direct economic counterparties are primarily research collaborators, licensors, and clinical development partners rather than commercial end customers. If its candidates are approved, the end users would be patients with rare neurological diseases, while commercialization would likely depend on specialty healthcare channels and potential licensing partners.

Research and development partners

Academic and third-party collaborators that support discovery, preclinical work, and clinical execution.

Licensing counterparties

Institutions and counterparties involved in licensing biological materials, IP, or legacy assets.

Clinical trial ecosystem

CROs, investigators, and trial sites that enable patient enrollment and study operations.

Future commercialization partners

Potential licensees or collaborators that could market approved therapies if the company does not commercialize alone.

Strategy

Neurogene's strategy is centered on advancing NGN-401 and other neurological gene therapy programs through clinical development and regulatory review. It also aims to build manufacturing capability, maintain intellectual property, and preserve optionality through partnerships or licensing if it chooses not to commercialize alone.

Advance lead clinical programsShort term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech company.

Strengthen manufacturing and CMC readinessShort term

Gene therapy products require specialized process control, supply reliability, and regulatory compliance.

Preserve financing flexibilityShort term

The company depends on external capital to fund ongoing R&D and future commercialization work.

Create commercialization optionalityMedium term

Approved products may be licensed to partners or sold through an internal sales force if built later.

Geography

Neurogene is headquartered in the United States and conducts its core research, development, and manufacturing activities there. The available disclosures do not provide a country revenue split, which is consistent with a pre-commercial biotechnology company whose operations are concentrated in development rather than product sales.

Risks

The company faces the typical risks of a clinical-stage biotechnology business: long development timelines, uncertain regulatory outcomes, and dependence on external capital. Its gene therapy focus adds manufacturing, supply-chain, and CMC complexity, while commercialization risk remains high because it has no established sales or distribution infrastructure.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Clinical development failure1Regulatory approval risk2Financing risk3Manufacturing and CMC risk4Commercialization risk5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Clinical development failureImpact: HighLikelihood: High

    Product candidates may not demonstrate safety or efficacy in trials.

    ExposureNGN-401NGN-101Early discovery programs
  2. Regulatory approval riskImpact: HighLikelihood: High

    FDA or foreign regulators may require additional data or decline approval.

    Exposure: Clinical and preclinical gene therapy programs

  3. Financing riskImpact: HighLikelihood: Medium

    Operations are funded primarily through external capital and future funding may be unavailable or costly.

    ExposureR&DClinical trialsCommercialization readiness
  4. Manufacturing and CMC riskImpact: HighLikelihood: Medium

    Biological products require validated processes, stable supply, and specialized controls.

    ExposureDrug substanceFormulationClinical supply production
  5. Commercialization riskImpact: MediumLikelihood: Medium

    The company has no sales force or distribution capability and may need partners.

    Exposure: Future approved products

Accounting

Judgemental items
Research and development expense recognition

Costs are expensed as incurred, so trial timing and manufacturing activity drive volatility.

Impact: Quarterly operating loss and comparability

Licensing revenue recognition

Revenue has been generated from upfront payments under legacy licensing agreements rather than product sales.

Impact: Reported revenue can be lumpy and non-recurring

Stock-based compensation

Employee equity awards are a recurring non-cash cost in a development-stage company.

Impact: Affects operating expenses and loss metrics

Valuation of acquired licenses and contingencies

License assets and related obligations may require judgment in measurement and disclosure.

Impact: Can affect balance sheet values and future expense recognition

Similar listed companies

Publicly listed companies with a comparable business focus.

Taysha Gene Therapies, Inc.

TSHA · Biological Products, (No Diagnostic Substances)

NervGen Pharma Corp

NGEN · Pharmaceutical Preparations

Forte Biosciences, Inc.

Pharmaceutical Preparations

PepGen Inc.

PEPG · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026

Neurogene Inc. (Nasdaq) – Pharmaceutical Preparations | Financial Analysis – Clarifo